Clinical Trial Update: Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating intravenous and intrathecal nivolumab for leptomeningeal disease in melanoma and non-small cell lung cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Lentiginous Melanoma
• Leptomeningeal Metastasis
• Melanoma
• Mucosal Melanoma
• Non-small Cell Lung Cancer
• Uveal Melanoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acral Lentiginous Melanoma, Central Nervous System Melanoma | Phase 1 | Status: RECRUITING